血友病B患者接受复合凝血因子IX的特征和治疗模式
Young-Shil Park1, Tai Ju Hwang2, Sang Kyu Park3
1Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of Korea.
Journal of clinical medicine
|July 12, 2025
概括
在B型血友病中,达到足够的因子IX (FIX) 暴露,而不仅仅是预防性标记,显著减少出血事件. 优化剂量和遵守监测对于更好的患者结果至关重要.
科学领域:
- 血液学 血液学 血液学
- 血液流动障碍 血液流动障碍
- 药物治疗 药物治疗
背景情况:
- 血友性B的指导方针推的因子IX (FIX) 预防在现实临床实践中往往没有得到满足.
- 剂量和患者坚持治疗的变化会影响治疗的有效性.
研究的目的:
- 评估治疗模式,坚持,FIX剂量及其与韩国血友B患者出血事件的相关性.
- 为了确定影响在B型血友病管理中预防出血的因素.
主要方法:
- 对130名接受FIX治疗的韩国血友病B患者进行了回顾性图表审查和调查.
- 使用回归模型分析年度出血事件 (ABE) 和每月出血.
- 在多变量分析中包含相关的共变量.
主要成果:
- 接受预防治疗的患者与不接受预防治疗的组相比,经历的ABE显著减少.
- 每月增加的FIX剂量增加与降低出血风险有关.
- 在调整后的模型中,患者遵守治疗方案并没有显示出与出血事件的独立关联.
结论:
- 在B型血友病中有效预防出血主要取决于已达到的因子IX (FIX) 暴露,而不是单独的预防分类.
- 目前的持续预防药物使用不足,剂量不足.
- 个性化剂量策略和持续的遵守监测对于改善血友B的结果至关重要.
相关概念视频
Venous Thrombosis III: Interprofessional Care
25
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
25
Anticoagulant Drugs: Low-Molecular-Weight Heparins
917
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
917
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis IV: Nursing Management
25
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
25
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
257
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
257


